Jun turnover is controlled through JNK-dependent phosphorylation of the E3 ligase itch

Science

Volumn 306, Issue 5694, 2004, Pages 271-275

  Gao, Min ^a   Labuda, Tord ^a,b   Xia, Ying ^a,d   Gallagher, Ewen ^a   Fang, Deyu ^c,e   Liu, Yun Cai ^c   Karin, Michael ^a  

^a San Diego   (United States)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

^d UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^e UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMICAL ACTIVATION; DEGRADATION;

LIGASES; PHOSPHORYLATION; PROTEOLYSIS;

PROTEINS;

F BOX PROTEIN; LIGASE; MITOGEN ACTIVATED PROTEIN KINASE; STRESS ACTIVATED PROTEIN KINASE INHIBITOR; TRANSCRIPTION FACTOR; UBIQUITIN;

BIOCHEMISTRY;

ANIMAL CELL; ARTICLE; CELL STIMULATION; CYTOKINE PRODUCTION; EFFECTOR CELL; ENZYME ACTIVITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN PHOSPHORYLATION; T LYMPHOCYTE; UBIQUITINATION;

ANIMALS; ANTIGENS, CD28; CD4-POSITIVE T-LYMPHOCYTES; INTERFERON TYPE II; INTERLEUKINS; LYMPHOCYTE ACTIVATION; MAP KINASE KINASE KINASE 1; MAP KINASE KINASE KINASES; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 8; MITOGEN-ACTIVATED PROTEIN KINASE 9; MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-JUN; RECEPTORS, ANTIGEN, T-CELL; RECOMBINANT FUSION PROTEINS; RNA, MESSENGER; T-LYMPHOCYTES; TH2 CELLS; UBIQUITIN; UBIQUITIN-PROTEIN LIGASES;

ANIMALIA;

EID: 5044225158     PISSN: 00368075     EISSN: None     Source Type: Journal    
DOI: 10.1126/science.1099414     Document Type: Article

References (27)

1. A. Varshavsky, Nature Cell Biol. 5, 373 (2003).
2. A. Hershko, A. Ciechanover, Anna. Rev. Biochem. 67, 425 (1998).
3. C. M. Pickart, Annu. Rev. Biochem. 70, 503 (2001).
4. M. Karin, Y. Ben-Neriah, Annu. Rev. Immunol. 18, 621 (2000).
5. P. K. Jackson, A. G. Eldridge, Mol. Cell 9, 923 (2002).
6. M. Karin, J. Biol. Chem. 270, 16483 (1995).
7. S. Gupta et al., EMBO J. 15, 2760 (1996).
8. A. M. Musti, M. Treier, D. Bohmann, Science 275, 400 (1997).
9. S. Y. Fuchs, L. Dolan, R. J. Davis, Z. Ronai, Oncogene 13, 1531 (1996).
10. A. S. Nateri, L. Riera-Sans, C. Da Costa, A. Behrens, Science 303, 1374 (2004).
11. D. Fang et al., Nature Immunol. 3, 281 (2002).
12. B. Li, C. Tournier, R. J. Davis, R. A. Flavell, EMBO J. 18, 420 (1999).
13. B. Hartenstein et al., EMBO J. 21, 6321 (2002).
14. C. Dong et al., Science 282, 2092 (1998).
15. C. Dong et al., Nature 405, 91 (2000).
16. L. Zhang et al., EMBO J. 22, 4443 (2003).
17. A. Minden et al., Science 266, 1719 (1994).
18. W. E. Paul, R. A. Seder, Cell 76, 241 (1994).
19. K. M. Murphy et al., Annu. Rev. Immunol. 18, 451 (2000).
20. C. S. Hsieh, S. E. Macatonia, A. O'Garra, K. M. Murphy, J. Exp. Med. 181, 713 (1995).
21. M. Gao, M. Karin, unpublished data.
22. K. Sabapathy et al., J. Exp. Med. 193, 317 (2001).
23. B. L. Bennett et al., Proc. Natl. Acad. Sci. U.S.A. 98, 13681 (2001).
24. T. Kallunki, T. Deng, M. Hibi, M. Karin, Cell 87, 929 (1996).
25. T. Borsello et al., Nature Med. 9, 1180 (2003).
26. T. Smeal, B. Binetruy, D. A. Mercola, M. Birrer, M. Karin, Nature 354, 494 (1991).
27. Ala construct. We thank A. Ciechanover and T. Hunter for helpful discussion and critique and L Chang and J. Park for assistance. M.G. was supported by a postdoctoral fellowship from the Damon Runyon Cancer Research Foundation. T.L. was supported by the Alfred Benzon Foundation and the LEO Pharma Research Foundation, Denmark. Work was supported by the Sandler Family Research Foundation and NIH grants AI43477, ES04151 and ES06376 to M.K. and by NIH grant R21AI48542 and a Research Scholar grant from the American Cancer Society (ACS) to Y.-C.L. M.K. is the Frank and Else Schilling ACS Research Professor.